Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352845 | 0.91 | SIRT2 (0.33) | KCNN4PTPN1USP2RAB9ACYP1A1 | |
| SCHEMBL4785402 | 0.81 | KCNN4 (0.37) | KCNN4PTPN1USP2RAB9ACYP3A4 | |
| SCHEMBL10159619 | 0.79 | TSHR (0.46) | KCNN4PTPN1CYP2C9CYP2C19 | |
| SCHEMBL1722405 | 0.77 | KCNN4 (0.39) | KCNN4USP2RAB9ACYP1A1CYP1B1 | |
| SCHEMBL15736923 | 0.77 | IDO1 (0.41) | KCNN4USP2RAB9ACYP1A1CYP1B1 | |
| SCHEMBL20603608 | 0.77 | KCNN4 (0.34) | KCNN4USP2RAB9ACYP1A1CYP1B1 | |
| SCHEMBL20603805 | 0.74 | KCNN4 (0.32) | KCNN4USP2RAB9ACYP1A1CYP1B1 | |
| SCHEMBL23232179 | 0.72 | ALDH1A1 (0.46) | KCNN4RAB9ACYP1A1CYP1B1CYP3A4 | |
| SCHEMBL1835047 | 0.72 | CYP1A1 (0.33) | KCNN4USP2RAB9ACYP1A1CYP1B1 | |
| SCHEMBL3746053 | 0.71 | LOXL2 (0.44) | KCNN4USP2RAB9ACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284286-B2 | Specific carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2016-03-15 | — | — | US | disclosed |
| EP-2951156-A1 | SPECIFIC CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-12-09 | — | — | EP | disclosed |
| EP-2406226-B1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014082737-A1 | SPECIFIC CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2014-06-05 | — | — | WO | disclosed |
| US-20140148468-A1 | SPECIFIC CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-8586755-B2 | Substituted nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-8178684-B2 | Substituted nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | disclosed |
| EP-2406226-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010102809-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234429-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148468-A1 | SPECIFIC CARBOXAMIDES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNQ3 | KCNN4 48/4885PTPN1 4631/4885USP2 2032/4885 |
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | KCNN4 75/4885PTPN1 4818/4885USP2 4427/4885 |
| US-20100234429-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNQ3 | KCNN4 66/4885PTPN1 3728/4885USP2 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.